Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADORA1 antisense RNA 1 (ADORA1-AS1) refers to a long non-coding RNA (lncRNA) species that is transcribed in the antisense direction relative to the ADORA1 (Adenosine A1 receptor) locus. Antisense RNAs are single-stranded RNA molecules that are complementary to messenger RNA (mRNA) and can regulate gene expression by various mechanisms, including blocking translation, influencing mRNA stability, or recruiting chromatin modifiers to the gene locus. They can function in *cis* (at the site of their transcription) or *trans* (at different loci). While naturally occurring antisense RNAs are well documented in the literature as gene expression regulators, there is no evidence that ADORA1-AS1 itself encodes a protein or functions as a druggable target; rather, it may influence the expression of the ADORA1 gene. No confirmed role as a receptor, enzyme, transporter, or conventional drug target is established for ADORA1-AS1. Important notes: - is_incorrect is set to true because ADORA1-AS1 is not a classical drug target. It is a non-coding RNA and has not been established as a receptor, enzyme, transporter, or molecule directly amenable to therapeutic drugs. - The entry might be due to confusion with ADORA1 (Adenosine A1 receptor), which is a well-known G protein-coupled receptor (GPCR) and therapeutic target, but ADORA1-AS1 itself is not. - No disease associations, interacting drugs, mechanisms of action, biomarkers, or safety concerns have been reported specifically for ADORA1-AS1. If structured information on ADORA1 (Adenosine A1 receptor) is needed instead, that would be a classical drug target involved in neuromodulation, sleep regulation, cardiovascular functions, and has documented agonists and antagonists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADORA1 antisense RNA 1 (ADORA1-AS1).